CTOs on the Move


 
Calyxt, Inc. is a consumer-centric, food- and agriculture-focused company based in Roseville, Minnesota. Our mission is to address health challenges such as obesity, diabetes, high cholesterol and food allergies by developing healthier food ingredients that produce high-quality, convenient and delicious food, while also providing agriculturally advantageous crop traits to farmers. As a leader in our field, our team is positively changing the way Americans eat by pioneering a paradigm shift to help make the food you love a healthier choice™.
  • Number of Employees: 1K-5K
  • Annual Revenue: $500M-1 Billion
  • www.calyxt.com
  • 2800 Mount Ridge Road
    Roseville, MN USA 55112
  • Phone: 651.683.2807

Executives

Name Title Contact Details
Vijay Gullapalli
Vice President of Artificial Intelligence, Machine Learning and Data Science Profile
Paul Weier
Director Of Information Technology Profile
Travis Frey
Chief Technology Officer Profile

Funding

Calyxt raised $60.9M on 05/22/2018

Similar Companies

Banyan Biomarkers Inc

Banyan Biomarkers Inc is a Alachua, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Astex Pharmaceuticals

Astex Pharmaceuticals is a Dublin, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Scout.com Inc

Scout.com Inc is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Inhibitex

Inhibitex, Inc. is a Alpharetta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Autolus

Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the Company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors.